To our surprise, DT-061 treatment drove a marked increase in cleaved caspase-9 and cleaved PARP expression in the absence of Bax activation in mock- as well as agonist mix–treated CLL cells (Figure 4A). This evidence concerns the gene BAX and B-cell chronic lymphocytic leukemia.